Hikma Pharmaceuticals PLC closed 0.61% short of its 52-week high of £22.96, which the company reached on January 31st.

Hikma Pharmaceuticals PLC HIK shares advanced 1.97% to £21.72 Monday, on what proved to be an all-around positive trading ...

Hikma Pharmaceuticals (LON:HIK – Free Report) had its price objective lifted by Berenberg Bank from GBX 2,400 ($29.74) to GBX 2,560 ($31.73) in a research note published on Wednesday morning, ...

London – M42, a global health leader powered by artificial intelligence (AI), and Hikma Pharmaceuticals PLC (Hikma), ...

The introduction of the Shield™ test for colorectal cancer screening marks a transformative step in advancing precision and ...

Billings, compares the state’s purchase of overdose reversal drugs like Narcan from companies that have contributed to the ...

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced an agreement with the Abu Dhabi ...

Pharmaceutical Industry Analysis in Saudi ArabiaThe pharmaceutical industry analysis in saudi arabia is poised for significant expansion over the coming decade, according to a new report by Future ...

Public health experts have concerns about the opioid reversal agent Opvee. But the company that makes it, Indivior, has found ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Guardant Health (GH) announced an agreement with the Abu Dhabi Public Health Center ADPHC to introduce a non-invasive blood-based screening ...